Modification of the Rheumatoid Arthritis (RA) Patient Reported Experience Measure (PREM) for patients with Interstitial Lung Disease (ILD)

J. Mandizha (Exeter, United Kingdom), A. Duckworth (Exeter, United Kingdom), H. Almond (Exeter, United Kingdom), G. Brown (Exeter, United Kingdom), S. Lines (Exeter, United Kingdom), A. Jorge Da Ponte (Exeter, United Kingdom), R. Shuttleworth (Exeter, United Kingdom), J. Lanario (Plymouth, United Kingdom), M. Steward (Exeter, United Kingdom), R. Sayers (Exeter, United Kingdom), C. Scotton (Exeter, United Kingdom), M. Gibbons (Exeter, United Kingdom), A. Russell (Exeter, United Kingdom)

Source: International Congress 2022 – Clinical problems in respiratory medicine: 1

Session: Clinical problems in respiratory medicine: 1
Session type: Thematic Poster
Number: 152

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Mandizha (Exeter, United Kingdom), A. Duckworth (Exeter, United Kingdom), H. Almond (Exeter, United Kingdom), G. Brown (Exeter, United Kingdom), S. Lines (Exeter, United Kingdom), A. Jorge Da Ponte (Exeter, United Kingdom), R. Shuttleworth (Exeter, United Kingdom), J. Lanario (Plymouth, United Kingdom), M. Steward (Exeter, United Kingdom), R. Sayers (Exeter, United Kingdom), C. Scotton (Exeter, United Kingdom), M. Gibbons (Exeter, United Kingdom), A. Russell (Exeter, United Kingdom). Modification of the Rheumatoid Arthritis (RA) Patient Reported Experience Measure (PREM) for patients with Interstitial Lung Disease (ILD). 152

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.